ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years
Clinical Lymphoma Myeloma and Leukemia(2022)
摘要
MorphoSys AG.
更多查看译文
关键词
ABCL,tafasitamab,lenalidomide,DLBCL,L-MIND,Phase II
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要